- Dr. Dennis Slamon, 2007 Gairdner Awardee from UCLA, is responsible
for the new breast cancer drug that can halt the spread of breast
cancer in one-in-three patients.
- Lecture MC'd by Pamela Wallin, with panelists Dr. Tak Mak, Princess
Margaret Hospital; Dr. Kathleen Pritchard, Sunnybrook Hospital and
Linda Priest, Medical Reporter, Globe and Mail
- Gairdner Public Lecture is free and open to everyone.
TORONTO, Oct. 4 /CNW/ - One of the five 2007 Gairdner International Award
winners will explain the new opportunities that molecular diversity brings to
creating cures for breast cancer.
Dr. Dennis Slamon has already changed the paradigm for cancer treatment
and has saved the lives of thousands of women with his breakthrough work that
targeted a specific genetic alteration which occurs in about 30 per cent of
breast cancer patients. Dr. Slamon's work led to the development of Herceptin,
the first in a new generation of cancer drugs and vaccines that can halt or
significantly slow the development of specific cancers.
Dr. Slamon's lecture will take place on Tuesday, October 23rd from
7:30 p.m. to 9:00 p.m. in the main auditorium at MaRS, 101 College Street.
Following the lecture, host Pamela Wallin will direct a discussion and
audience questions with panelists Dr. Tak Mak from Princess Margaret Hospital,
Dr. Kathleen Pritchard from Sunnybrook Hospital and Lisa Priest, medical
reporter for the Globe and Mail. Admission is free and seating is reserved.
Confirmation is required. Members of the media who wish to attend, please call
Bob Ramsay at 4l6 598 3970, or e-mail: firstname.lastname@example.org.
Dennis Slamon is the Director of Clinical/Translational Research at the
Jonsson Comprehensive Cancer Center at the University of California, Los
Angeles (UCLA). He is also Director of the Revlon/UCLA Women's Cancer Research
Program at the Jonsson Center; chief of the division of Hematology/Oncology
and Executive Vice Chair for Research at UCLA's Department of Medicine. In
2000, Dr. Slamon was appointed by U.S. President Bill Clinton to the
three-member President's Cancer Panel, and in 2004, the American Cancer
Society presented Dr. Slamon with the Medal of Honor, the top award bestowed
by the organization.
Dr. Slamon is also a passionate and highly articulate translator of
'basic research' into greater public understanding of the challenges and
opportunities surrounding new cancer treatments.
The Gairdners (www.gairdner.org), now in their 48th year have grown to be
one of the most prestigious awards in all of science, recognizing outstanding
contributions by medical scientists worldwide, whose work will significantly
improve the quality of life. Of the 283 Gairdner awardees, 68 have gone on to
win the Nobel Prize.
The Gairdner Public Lecture is sponsored by Purdue Pharma, MaRS and The
Globe and Mail.
Since 2003, the Canadian Institutes for Health Research (CIHR) has been
the national sponsor of the Gairdner Awards. CIHR is the major federal agency
responsible for funding health research in Canada, supporting the work of
10,000 researchers in universities, teaching hospitals and research institutes
across Canada. The results are improved health for Canadians, more effective
health services and products, and a strengthened Canadian health care system.
For further information:
For further information: Bob Ramsay, (4l6) 598-3970, email@example.com